Samuel J Klempner
Overview
Explore the profile of Samuel J Klempner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
4096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hyung S, Ko J, Heo Y, Blum S, Kim S, Park S, et al.
Sci Adv
. 2023 Nov;
9(47):eadk1098.
PMID: 38000030
Gastric cancer (GC) with peritoneal metastases and malignant ascites continues to have poor prognosis. Exosomes mediate intercellular communication during cancer progression and promote therapeutic resistance. Here, we report the significance...
22.
Jarnagin J, Saraf A, Baiev I, Chi G, Van Seventer E, Mojtahed A, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2343512.
PMID: 37976066
Importance: Patient-reported outcomes (PROs), such as quality of life (QOL) and symptoms, are often associated with clinical outcomes in patients with cancer. In practice, oncologists use serum tumor markers (TMs)...
23.
Kasi P, Bucheit L, Liao J, Starr J, Barata P, Klempner S, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300118.
PMID: 37769226
Purpose: Immune checkpoint inhibitors are approved for advanced solid tumors with microsatellite instability-high (MSI-H). Although several technologies can assess MSI-H status, detection and outcomes with circulating tumor DNA (ctDNA)-detected MSI-H...
24.
Taylor M, Wu C, Fridy P, Zhang S, Senussi Y, Wolters J, et al.
Cancer Discov
. 2023 Sep;
13(12):2532-2547.
PMID: 37698949
Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and...
25.
Klempner S, Lee K, Shitara K, Metges J, Lonardi S, Ilson D, et al.
Clin Cancer Res
. 2023 Jul;
29(19):3882-3891.
PMID: 37490286
Purpose: Zolbetuximab, an IgG1 monoclonal antibody, binds to claudin 18.2 (CLDN18.2) and mediates tumor cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. We sought to examine zolbetuximab combinations in...
26.
Singh H, Klempner S, Melnitchouk N, Chander D, Negrea O, Patel A, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200572.
PMID: 37343200
Purpose: GI cancers commonly spread to the peritoneal cavity, particularly from primary adenocarcinomas of the stomach and appendix. Peritoneal metastases are difficult to visualize on cross-sectional imaging and cause substantial...
27.
Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner S, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37277193
Background: Subgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gastric or gastroesophageal...
28.
Huffman B, Jurdi A, Aleshin A, Liu M, Klempner S
JCO Precis Oncol
. 2023 Mar;
7:e2300043.
PMID: 36952643
No abstract available.
29.
Graf R, Fisher V, Creeden J, Schrock A, Ross J, Nimeiri H, et al.
Cancer Res Commun
. 2023 Mar;
2(9):1037-1048.
PMID: 36922935
Significance: Using real-world data, we sought to evaluate robustness of these clinical associations using the same assay platform and biomarker cut-off point used in both clinical trials and pan-tumor CDx...
30.
Taylor M, Connie W, Fridy P, Zhang S, Senussi Y, Wolters J, et al.
bioRxiv
. 2023 Feb;
PMID: 36747644
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. While proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for...